NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Antibody and Protein Therapeutics Sector Outlook — September 2026

This report maps the Antibody and Protein Therapeutics sector into three EV / Revenue (CY2027E) valuation tiers across 63 companies, examines what separates the top of the range from the bottom, and reviews nine precedent transactions. Built for boards, owners and corporate development teams tracking this space.

For information only. Not an appraisal or a fairness opinion.

What moved since: Antibody and Protein Therapeutics M&A update, 14–28 September 2026

Key figures

Sector median multiple
5.8x
EV / Revenue (CY2027E)
Top-tier multiple
17.6x
EV / Revenue (CY2027E), top 8 names
Bottom-tier multiple
1.2x
EV / Revenue (CY2027E), bottom 8 names
Margin-cohort spread
4.9x
Higher-margin cohort vs 2.0x lower-margin

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ANTIBODY AND PROTEIN THERAPEUTICS

Antibody and Protein Therapeutics: One Label, Three Tiers

Where enterprise value sits across the antibody and protein therapeutics set, what the two ends of the range have in common, and what recent acquirers agreed to pay for whole companies.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Antibody and Protein Therapeutics trades as three priced tiers on EV / Revenue (CY2027E): the top eight names sit at 17.6x, the bottom eight at 1.2x, against a sector median of 5.8x. That spread sits inside the clinical-stage biologics group, which accounts for 60 of the 63 companies covered, while the smaller product-revenue group prices well below it. Acquirers have kept buying across the range, from smaller cash-adjusted deals to a 9.9x revenue multiple, suggesting fit within an existing franchise matters as much as stage.

Key findings

  • The sector splits into three price tiers, from 17.6x at the top to 1.2x at the bottom
  • Clinical-stage biologics developers (60 of 63 names) hold the sector's full price range
  • Margin split is stark: names above the median margin carry 4.9x versus 2.0x below it
  • Acquirers kept buying through the repricing, from $88M deals to 9.9x revenue multiples

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ANTIBODY AND PROTEIN THERAPEUTICS

    This is the cover page introducing NeuraCap's September 2026 sector outlook on Antibody and Protein Therapeutics.

    We open with the finding that carries the whole report: this sector trades as three priced tiers, and the spread sits inside the clinical-stage group. Everything that follows walks through where that tier boundary sits and what separates the top of the range from the bottom — so what matters is knowing which tier your company sits in before you set expectations.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ANTIBODY AND PROTEIN THERAPEUTICS Antibody and Protein Therapeutics: One Label, Three Tiers Where enterprise value sits across the antibody and protein therapeutics set, what the two ends of the range have in common, and what recent acquirers agreed to pay for whole companies. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page lists the five report sections plus the appendix that make up the deck.

    We walk through the roadmap here: the bottom line, the landscape, valuation and situations, precedent transactions, and strategic implications, with full detail held in the appendix. We put the bottom line first by design, so even a reader who stops after section one leaves with the complete story — so what: you can dig as deep as you need without missing the headline.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line One Sector Label, Three Different Price Tiers 02 The Landscape 60 of the 63 Names Are Clinical-Stage Developers 03 Valuation & Situations The Gap Between the Top and the Bottom of the Range Is the Finding 04 Precedent Transactions Acquirers Kept Buying Through the Repricing 05 Strategic Implications What a Management Team Can Actually Move 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Antibody and Protein Therapeutics Trades as Three Priced Tiers, Led by Clinical-Stage Biologics Developers

    This page presents the report's central finding that the sector trades in three priced tiers led by clinical-stage biologics developers.

    On an EV / Revenue (CY2027E) basis, the sector median sits at 5.8x, with the top eight names at 17.6x against 1.2x at the bottom of the range. We rely on this forward-revenue lens because it is the basis validated across the largest share of the coverage set, 32 of 63 companies. So what: the size of that top-to-bottom gap is the strategic question this report answers, not a rounding error in the data.

    Everything on this page

    01 · THE BOTTOM LINE Antibody and Protein Therapeutics Trades as Three Priced Tiers, Led by Clinical-Stage Biologics Developers The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (32 of 63 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (32 of 63 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Distance Between the Top and the Bottom Is a Strategy Question, Not a Rounding Error The middle of the set sits at 5.8x CY2027E revenue. The eight names at the top sit at 17.6x and the eight at the bottom at 1.2x, with a revenue lens used here alongside only 6 of the 63 companies carrying a meaningful forward EBITDA. 2 Growth Shows up in the Price, but It Does Not Split the Set Cleanly The 13 names growing above the covered middle growth rate sit at 6.7x; the 12 below it sit at 3.2x. The two groups overlap: 4 names hold a multiple above the middle of the set while their forecast revenue line runs below it. 3 Almost the Whole Set Is Clinical-Stage, and That Is Where the Range Lives 60 of the 63 companies are clinical-stage biologics developers, and the 29 of them carrying a CY2027E revenue estimate sit at 6.2x. The 3 adjacent-model names, which carry product revenue today, sit at 2.0x. 4 Buyers Have Stayed in the Market at Both Ends of the Range Across the 9 transactions shown, acquirers run from large-cap pharmaceutical buyers to mid-cap consolidators: AbbVie Inc. announced ImmunoGen, Inc. at 9.9x revenue, and Merck & Co., Inc. completed Harpoon Therapeutics, Inc. at $88M. Consideration in this sector is customarily unbundled across upfronts, milestones and contingent value rights. 5.8x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 3 of 63 names are… 17.6x Premium end EV/Revenue vs 1.2x at the discount end top quartile (n=8) against bottom quartile (n=8) on EV/Revenue — the spread the report explains 16 Transactions with disclosed terms 53 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces the market map section, covering the two business-segment groups that make up the sector.

    We use this page to reset before showing how the sector splits by business segment. The section ahead shows two groups and the price gap sitting between them — so what: segment, not size, is the first cut that explains where value sits.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE 60 of the 63 Names Are Clinical-Stage Developers Two groups on the page, and the price gap between them. 02 of 06 Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    95% of the Names Sit in One Segment, and the Range Runs Top to Bottom Inside It

    This page shows that 95% of the covered companies sit in one business segment, and the valuation range runs from top to bottom inside it.

    Grouping all 63 companies by business segment, we find 95% sit in a single segment, with the group median calculated on rated names only. That means the top-tier and bottom-tier names we highlight later are not different segments — they are different positions inside the same one. So what: segment alone does not explain the spread; something else inside that segment does.

    Everything on this page

    02 · MARKET MAP 95% of the Names Sit in One Segment, and the Range Runs Top to Bottom Inside It 63 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE BIOLOGICS DEVELOPERS 60 cos median 6.2x argenx SE (ARGX) Genmab A/S (GMAB) Roivant Sciences (ROIV) BioMarin (BMRN) ImmunityBio (IBRX) TG Therapeutics (TGTX) Immunovant (IMVT) Scholar Rock (SRRK) Kodiak Sciences (KOD) Oruka Therapeutics (ORKA) Dianthus (DNTH) Arcus Biosciences (RCUS) ADMA Biologics (ADMA) Xencor (XNCR) Celldex (CLDX) Viridian (VRDN) Inhibrx (INBX) Absci (ABSI) Omeros (OMER) Vir Biotechnology (VIR) Zenas BioPharma (ZBIO) Savara (SVRA) Corvus (CRVS) Bicara (BCAX) OmniAb (OABI) Annexon (ANNX) MoonLake (MLTX) Cullinan (CGEM) Shattuck Labs (STTK) +31 more Value here is a probability-weighted view of launch scenarios, so the forward revenue line captures only part of what a buyer underwrites. ADJACENT MODELS 3 cos median 2.0x Grifols, S.A. (GRFS) Kiniksa (KNSA) Kamada (KMDA) Three businesses with product revenue on the books today, priced off delivered economics rather than the next pivotal readout.

  6. 06
    02 · LANDSCAPE

    Clinical-Stage Developers Set the Sector's Range; The Product-Revenue Names Sit Below It

    This page shows that clinical-stage developers set the sector's valuation range while product-revenue names sit below it.

    The clinical-stage developer group sets the top and the middle of the sector's range, while the smaller product-revenue group prices below it. This split is drawn from group medians on rated names only, with full company detail available in the appendix. So what: benchmark your multiple against the clinical-stage group, not the sector average, if that is where your business sits.

    Everything on this page

    02 · LANDSCAPE Clinical-Stage Developers Set the Sector's Range; The Product-Revenue Names Sit Below It Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage biologics developers 60 95% 6.2x argenx SE (ARGX) · Genmab A/S (GMAB) · +58 more Sixty names, one pricing spectrum. 60 of the 63 companies sit here, from FcRn and bispecific franchises to early linker-payload platforms. The 29 carrying a CY2027E revenue estimate sit at 6.2x, and the spread inside this one group runs from the top tier of the set to the bottom. Adjacent models 3 5% 2.0x Grifols, S.A. (GRFS) · Kiniksa Pharmaceuticals, Ltd. (KNSA) · +1 more Three product-revenue businesses. Grifols, S.A. (GRFS), Kiniksa Pharmaceuticals, Ltd. (KNSA) and Kamada Ltd. (KMDA) carry commercial revenue today, and the 3 names sit at 2.0x. Diligence on businesses like these turns on collection and manufacturing capacity, delivered gross margin and payer mix rather than a single readout.

  7. 07
    SECTION 03

    03

    This divider introduces the valuation section, where the gap between the top and bottom of the range is the finding.

    We reset here before turning to valuation itself. Of the 63 companies in the universe, 32 carry a CY2027E revenue estimate, and it is the gap between the top and the bottom of that rated set that the next few pages unpack — so what: the coverage gap itself tells you how much of the sector the forward lens can actually price.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Gap Between the Top and the Bottom of the Range Is the Finding 63 companies on the page, of which 32 names carry a CY2027E revenue estimate. 03 of 06 Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    A Forward Lens Already Credits the Forecast — the Top of the Range Holds Its Premium Anyway

    This page compares the highest and lowest of the 32 rated companies on EV / Revenue (CY2027E) against the 5.8x sector median.

    Even though the forward lens already credits the forecast built into consensus, the top of the range holds its premium against the sector median of 5.8x, while the bottom trades well below it. We show the 12 highest and 12 lowest of the 32 rated companies, with the 8 mid-cohort names clustering near the median. So what: the premium at the top is not a forecast artefact — it persists after the forward numbers are already in the price.

    Everything on this page

    03 · PUBLIC MARKET VALUATION A Forward Lens Already Credits the Forecast — the Top of the Range Holds Its Premium Anyway EV / Revenue (CY2027E) · the 12 highest and 12 lowest of 32 rated companies · sector median 5.8x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (32 of 63 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (32 of 63 companies), so this report follows it. The 8 mid-cohort names cluster near the median; the full set is in the appendix and companion tables. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM END — the eight names at the top of the range, at 17.6x · median 17.6x DISCOUNT END — the eight names at the bottom of the range, at 1.2x · median 1.2x Sector median 5.8x WHAT SEPARATES THE TWO ENDS The top is clinical-stage. The eight names at the top of the range are clinical-stage biologics developers, among them Vir Biotechnology, Inc. (VIR), Xencor, Inc. (XNCR) and OmniAb, Inc. (OABI). The premium sits alongside platform breadth, engineered-Fc and masked-antibody programmes and partner-funded work, rather than alongside delivered product revenue. The bottom carries product revenue. The bottom of the range includes Grifols, S.A. (GRFS), Kamada Ltd. (KMDA) and ADC Therapeutics S.A. (ADCT), businesses with revenue already on the books. A revenue multiple is a harder lens for a company selling product today than for one whose forecast line is still small. A forward lens already credits growth. CY2027E revenue embeds the consensus forecast, so a premium that survives that lens is a statement about durability rather than near-term pace. Clearing the middle of the range on a forward number is the harder of the two tests.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 32% Margin Line Carry 4.9x Against 2.0x Below It

    This page splits the rated companies by margin and by growth cohort to show what separates the top of the range from the bottom.

    Splitting the rated set at its own covered median, names above the 32% margin line carry 4.9x against 2.0x for names below it. Growth cuts the set less cleanly than margin does on this basis. So what: margin, more than growth, is the variable that lines up with where a company sits in the range — an association this data supports, not a guaranteed causal driver.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 32% Margin Line Carry 4.9x Against 2.0x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=13; slower n=12; higher-margin n=3; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 18% · EBITDA-margin split at 32% The Faster-Growing Names Sit Higher, and the Two Groups Still Overlap Across the 32 names with a CY2027E revenue estimate, the 13 growing above 18% sit at 6.7x and the 12 below sit at 3.2x. The gap is visible, and it is narrower than the distance between the top and bottom tiers of the same set. Four Names Hold a High Multiple with a Falling Forecast Line Arcus Biosciences, Inc. (RCUS) at -40% and Xencor, Inc. (XNCR) at -13% sit above the middle multiple with forecast revenue declining. In this sector the reported revenue line often reflects collaboration and milestone income, so a falling line is not the same signal it would be in a product business. Five Names Grow Above the Middle and Still Price Below It Compugen Ltd. (CGEN), Whitehawk Therapeutics Inc (WHWK) and Invivyd, Inc. (IVVD) are among the 5 names with above-middle growth sitting below the middle multiple. Where forecast pace is credited and where it is not is a question a board can test against its own readout calendar and its owned-versus-partnered economics. Thin Profit Coverage Keeps This Set on a Revenue Lens 6 of the 63 companies carry a meaningful forward EBITDA, which leaves the revenue line doing most of the work in peer comparison. Diligence in this sector tests cash runway to the next value-inflecting readout alongside the forecast revenue line, and prices the patent estate and freedom to operate separately.

  10. 10
    03 · SITUATION MAP

    Eight Names Clear Both the Growth Bar and the Margin Bar; Nine Clear Only One

    This page maps rated companies against the sector median multiple and the covered median growth rate to define four situations.

    Cutting the rated set on the 5.8x sector median and the 18% covered median growth rate, eight names clear both bars and nine clear only one. Seven rated names without a second measure are left off this map. So what: this is a way to place your own company inside the same two-axis cut before deciding what to do about it — it characterises situations, not recommendations.

    Everything on this page

    03 · SITUATION MAP Eight Names Clear Both the Growth Bar and the Margin Bar; Nine Clear Only One Cut on EV / Revenue vs the sector median (5.8x) (rows) and revenue growth vs the covered median (18%) (columns) · 7 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up and Growing Above-median multiple · above-median revenue growth 8 names argenx SE (ARGX) · Kiniksa Pharmaceuticals, Ltd. (KNSA) · ImmunityBio, Inc. (IBRX) · +5 more 8 names sit above the middle multiple and above the middle growth rate, among them argenx SE (ARGX), TG Therapeutics, Inc. (TGTX) and Omeros Corporation (OMER). For a company here the work is holding the forecast through the next readout, since the forward lens already credits it. Priced up on Something Other than Pace Above-median multiple · below-median revenue growth 4 names Arcus Biosciences, Inc. (RCUS) · Xencor, Inc. (XNCR) · Zura Bio Limited (ZURA) · +1 more 4 names hold an above-middle multiple with a below-middle forecast growth line, including Arcus Biosciences, Inc. (RCUS) and ALX Oncology Holdings Inc. (ALXO). Collaboration and milestone revenue can move a reported line without changing pipeline value, and diligence will test which is which. Growing Without the Multiple Below-median multiple · above-median revenue growth 5 names ImmuCell Corporation (ICCC) · Invivyd, Inc. (IVVD) · Compugen Ltd. (CGEN) · +2 more 5 names grow faster than the middle of the set while pricing below it, including Compugen Ltd. (CGEN) and Invivyd, Inc. (IVVD). Revenue quality, owned-versus-partnered economics and label-expansion breadth are the levers a management team here controls directly. Below Both Lines Below-median multiple · below-median revenue growth 8 names Genmab A/S (GMAB) · Grifols, S.A. (GRFS) · BioMarin Pharmaceutical Inc. (BMRN) · +5 more 8 names sit below both lines, among them Genmab A/S (GMAB), Grifols, S.A. (GRFS) and BioMarin Pharmaceutical Inc. (BMRN). Several carry substantial product revenue, where a forward revenue multiple is the harder lens and mix, pricing and cost structure carry the story.

  11. 11
    03 · THE AGENDA

    Revenue Mix, Pricing and Retention Stay in a Board's Hands Before the Next Readout

    This page frames the operating questions a board can resolve before the next clinical readout.

    We frame revenue mix, pricing and retention as the levers that stay inside a board's control before the next readout changes the picture. These are observations on what the data puts on the table, not a recommendation to act. So what: the questions here are ones a management team can start working through now, independent of what the market does next.

    Everything on this page

    03 · THE AGENDA Revenue Mix, Pricing and Retention Stay in a Board's Hands Before the Next Readout NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Decide Whether You Own the Chemistry or Rent It The top of this range sits alongside companies that hold their own engineering — linker-payload chemistry, Fc design, masked-antibody control. In-licensed enabling technology brings royalty stacking and freedom-to-operate dependencies that narrow delivered economics at launch. What changes the answer: A licensor stack or third-party Fc claim that materially thins the net royalty at your expected launch. Settle Whether the Story Is One Asset or an Engine Repeat partner validation across programmes reads differently from a single pivotal readout carrying the whole value. OmniAb, Inc. (OABI) and other platform-facing names sit at the top of this range without a commercial product behind them. What changes the answer: A second partner-funded programme reaching dose expansion on the same platform. Choose Which Rights You Keep and Which You Place Territorial carve-outs — retaining or placing Greater China or Japan rights separately — are ordinary in this sector. Partnering funds the runway to the next inflection, and it also moves downstream royalty away from the balance sheet that a buyer would credit. What changes the answer: A territorial offer priced against your own peak-sales view rather than against current burn. Shape the Revenue Mix a Revenue Lens Actually Rewards With most of this set read on forward revenue, the composition of that line matters: milestone and collaboration income behaves differently from product sales in a peer comparison. Mix, pricing and the pace of label expansion are the parts a management team sets. What changes the answer: A milestone-heavy year that lifts the reported line without changing the pipeline behind it.

  12. 12
    SECTION 04

    04

    This divider introduces the precedent transactions section, covering nine disclosed deals.

    We reset here before the deal evidence. Acquirers kept buying through the sector's repricing, and the record we show runs from large-cap pharmaceutical buyers to mid-cap consolidators — so what: the buyer side of this market has stayed active across the range, not just at the top of it.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Acquirers Kept Buying Through the Repricing 9 transactions in the record, from large-cap pharmaceutical buyers to mid-cap consolidators. 04 of 06 Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Announced Deal Prices Mark Where Buyers Have Been Willing to Value Whole Companies Here

    This page walks through three of the sector's precedent transactions as case studies on the prices buyers have paid for whole companies.

    We use three of the sector's disclosed transactions to show where buyers have been willing to value whole companies: AbbVie Inc. announced ImmunoGen, Inc. at 9.9x revenue, and Merck & Co., Inc. completed Harpoon Therapeutics, Inc. at $88M. These multiples sit on LTM financials at announcement, not on the CY2027E public basis, so no direct spread is claimed between the two. So what: these are real prices buyers have agreed to pay in this sector, and they set a reference point independent of where public multiples sit today.

    Everything on this page

    04 · DEAL CASE STUDIES Announced Deal Prices Mark Where Buyers Have Been Willing to Value Whole Companies Here 3 of 16 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 67 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Sep-2025 $7.6B Genmab A/S acquires Merus N.V. EV / LTM revenue 1.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Genmab A/S sits in this set as a clinical-stage biologics developer, and Merus N.V. brings programmes in the same modality neighbourhood. The transaction suggests a buyer consolidating depth inside a modality it already runs, rather than buying entry into a new one. HOW THE TARGET WAS VALUED Recorded at $7.6B with 1.1x on revenue. A low revenue multiple against a large disclosed value points to a target priced on its pipeline rather than on its current revenue line, which is how most of the clinical-stage names in this set are read. Sep-2022 $628M Sesen Bio, Inc. acquires Carisma Therapeutics Inc. EV / LTM revenue 26.7x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Buyers in this record cluster into two groups: large-cap pharmaceutical acquirers replacing revenue ahead of exclusivity expiries, and mid-cap biopharma adding depth in a therapeutic franchise where a salesforce already sits. Where buyer and target share a modality or an indication, the logic the transaction suggests is franchise depth rather than entry into new ground. HOW THE TARGET WAS VALUED Clinical-stage targets in this sector are customarily priced against cash-adjusted enterprise value, with the balance sheet treated as a near-dollar-for-dollar credit. Benchmarked against the peer set, a revenue multiple on a target like this reads as a proxy for pipeline value rather than delivered product economics. Apr-2023 $471M Jazz Pharmaceuticals, Inc. acquires Zymeworks Zanidatamab Inc. EV / LTM revenue 1.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Deals here are commonly structured as an upfront payment with development and commercial milestones behind it, and increasingly carry contingent value rights that bridge disagreement over a binary readout or a label breadth assumption. Territorial carve-outs and option-to-acquire structures are ordinary rather than exceptional in this record. HOW THE TARGET WAS VALUED Headline value in structures of this kind reflects the signing payment, while the balance sits behind clinical and regulatory events. Against the peer set, that makes disclosed multiples a floor on what the asset could ultimately earn rather than a settled price.

  14. 14
    SECTION 05

    05

    This divider introduces the strategic implications section, covering the operating levers a management team controls.

    We reset here before turning from the market evidence to what a management team can actually move. The levers ahead sit inside the company, not in the market — so what: this is the part of the range you can influence directly, whatever tier you start in.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What a Management Team Can Actually Move Operating levers that sit inside the company rather than in the market. 05 of 06 Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Value in This Sector Separates on Growth and Margin, and Both Are Operating Choices

    This page argues that growth and margin, the two variables that separate the top of the range from the bottom, are operating choices.

    Because growth and margin are the two variables that separate the top of this range from the bottom, and both sit inside a management team's own operating choices, the questions on this page are ones the data puts directly on the table for the next twelve months. So what: the separation this report documents is not fixed by market conditions alone — a management team has real levers to move its own position.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Value in This Sector Separates on Growth and Margin, and Both Are Operating Choices NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Your Multiple Is Set Inside the Clinical-Stage Group, Not Against the Sector Average 60 of the 63 companies here are clinical-stage biologics developers, and the full range from top tier to bottom tier sits inside that one group. The comparison that matters is against the names running your modality and therapeutic area, on the same forward lens. FOR BOARDS Runway to the Next Readout Is the Variable Diligence Keeps Returning To With only 6 of the 63 companies carrying a meaningful forward EBITDA, a buyer underwrites cash to the inflection, the patent estate and freedom to operate. Build-versus-buy on enabling chemistry, and the order in which indications are sequenced, are decisions taken well before any counterparty is in the room. FOR PARTNERS AND ACQUIRERS The Record Shows Buying at Both Ends of the Range Across the 9 transactions shown, disclosed values run from small cash-adjusted purchases of clinical-stage developers to the largest deal in the record, and structures unbundle consideration across upfronts, milestones and contingent value rights. Fit within an existing franchise is the common thread among the strategic buyers on this page.

  16. 16
    SECTION 06

    06

    This divider introduces the appendix, covering the full comparables universe, methodology and sources.

    We close the argument here and open the appendix, which carries the comparables detail behind every figure shown earlier, the valuation basis, and where each underlying disclosure lives — so what: every number in this deck traces back to a source you can open yourself.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This page lists the first half of the public comparables set, grouped by valuation tier against the 5.8x sector median.

    We show the comparables here with shading marking names above and below the 5.8x sector median, covering 32 rated companies out of the 63 in the universe. Tickers link through to the underlying source for each company shown. So what: you can check any single name's position against the tier structure directly from this table.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (5.8x); amber marks below · 32 rated companies; 31 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 30 of 32 rated names shown here; the remaining 2 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥12.1x · median 17.6x · 8 companies Arcus Biosciences, Inc. RCUS Clinical-stage biologics developers $2.4B 52.0x -40% n/a n/a MoonLake Immunotherapeutics MLTX Clinical-stage biologics developers $594M 31.0x n/a n/a n/a ImmunityBio, Inc. IBRX Clinical-stage biologics developers $9.7B 21.9x 96% n/a n/a Vir Biotechnology, Inc. VIR Clinical-stage biologics developers $1.3B 17.9x n/a n/a n/a Zura Bio Limited ZURA Clinical-stage biologics developers $163M 17.4x 13% n/a n/a OmniAb, Inc. OABI Clinical-stage biologics developers $657M 15.1x 24% n/a n/a Xencor, Inc. XNCR Clinical-stage biologics developers $1.8B 14.3x -13% n/a n/a Adagene Inc. ADAG Clinical-stage biologics developers $69M 12.7x 18% n/a n/a CORE — 2.4x–12.1x · median 5.8x · 16 companies Cullinan Therapeutics, Inc. CGEM Clinical-stage biologics developers $569M 11.9x n/a n/a n/a ALX Oncology Holdings Inc. ALXO Clinical-stage biologics developers $60M 11.2x 16% n/a n/a Kiniksa Pharmaceuticals, Ltd. KNSA Biologics-led pharmaceutical developers $11.3B 9.2x 23% n/a n/a Janux Therapeutics, Inc. JANX Clinical-stage biologics developers $74M 8.5x n/a n/a n/a CytomX Therapeutics, Inc. CTMX Clinical-stage biologics developers $242M 8.0x 20% n/a n/a argenx SE ARGX Clinical-stage biologics developers $56.7B 7.4x 24% 33% 57 TG Therapeutics, Inc. TGTX Clinical-stage biologics developers $8.8B 6.7x 38% n/a n/a

  18. 18
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This page lists the second half of the public comparables set, grouped by valuation tier against the 5.8x sector median.

    This second table continues the same comparables view, still shaded against the 5.8x sector median across the 32 rated companies. Together with the prior page, it gives the full rated set behind every tier reference used earlier in the report. So what: the appendix, not just the summary pages, is where a client can verify any individual company's placement.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (5.8x); amber marks below · 32 rated companies; 31 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 30 of 32 rated names shown here; the remaining 2 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 2.4x–12.1x · median 5.8x · 16 companies Omeros Corporation OMER Clinical-stage biologics developers $1.3B 6.2x 72% n/a n/a Compugen Ltd. CGEN Clinical-stage biologics developers $88M 5.5x 57% n/a n/a Whitehawk Therapeutics Inc WHWK Clinical-stage biologics developers $54M 5.0x 24% n/a n/a ImmuCell Corporation ICCC Clinical-stage biologics developers $95M 5.0x 27% n/a n/a Genmab A/S GMAB Clinical-stage biologics developers $25.6B 4.9x 17% 36% 53 Prothena Corporation plc PRTA Clinical-stage biologics developers $141M 4.8x n/a n/a n/a ADMA Biologics, Inc. ADMA Clinical-stage biologics developers $2.4B 3.8x 18% 48% 65 Agenus Inc. AGEN Clinical-stage biologics developers $363M 2.6x -1% n/a n/a BioMarin Pharmaceutical Inc. BMRN Clinical-stage biologics developers $10.7B 2.4x 14% 26% 40 DISCOUNT — <2.4x · median 1.2x · 8 companies Sutro Biopharma, Inc. STRO Clinical-stage biologics developers $77M 2.2x -31% n/a n/a Grifols, S.A. GRFS Commercial-stage biologics franchises $18.2B 2.0x 6% 31% 38 Kamada Ltd. KMDA Specialty biologics and follow-on manufacturers $436M 1.9x 11% 29% 40 Alector, Inc. ALEC Clinical-stage biologics developers $41M 1.2x n/a n/a n/a Connect Biopharma Holdings Limited CNTB Clinical-stage biologics developers $17M 1.2x n/a n/a n/a Invivyd, Inc. IVVD Clinical-stage biologics developers $93M 1.1x 45% n/a n/a

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists the first half of the precedent transactions with disclosed terms, ordered newest first.

    We list the transactions with disclosed terms here, newest first, out of the larger recorded set behind them. Multiples shown are on LTM financials at announcement, and deal values link through to the underlying filing. So what: this is the primary evidence behind the deal prices referenced earlier in the report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 16 transactions with disclosed terms in this tier (53 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 67 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jan-2026 GlaxoSmithKline LLC → RAPT Therapeutics, Inc. $911M n/a n/a GlaxoSmithKline LLC announced the acquisition of RAPT Therapeutics, Inc. at $911M, the most recent transaction in this record. Large-cap acquirers replacing revenue ahead of exclusivity expiries have been persistent buyers of immunology-facing clinical assets. Nov-2025 Day One Biopharmaceuticals, Inc. → Mersana Therapeutics, Inc. $285M 8.6x n/a Day One Biopharmaceuticals, Inc. completed the purchase of Mersana Therapeutics, Inc. at $285M, recorded at 8.6x revenue. That mark sits above the middle of the peer set on the same revenue basis. Oct-2025 Novo Nordisk Health Care AG → Omeros Corporation $2.1B n/a n/a Novo Nordisk Health Care AG announced the acquisition of Omeros Corporation (OMER) at $2.1B. Omeros Corporation (OMER) also sits in the core tier of this set, with a forecast growth line above the covered middle. Sep-2025 Genmab A/S → Merus N.V. $7.6B 1.1x n/a Genmab A/S announced the acquisition of Merus N.V. at $7.6B, the largest disclosed value in this record, recorded at 1.1x revenue. Buyer and target both sit in the bispecific neighbourhood of this sector. Oct-2024 Aryzta AG (North America) → Zentalis Pharmaceuticals, Inc. n/a n/a 13.6x Aryzta AG (North America) announced a transaction for Zentalis Pharmaceuticals, Inc. recorded at 13.6x EBITDA, with no enterprise value disclosed. Profit multiples are uncommon in this record, and the revenue lens carries most of the comparison. Apr-2024 Merck & Co., Inc. → Harpoon Therapeutics, Inc. $88M 2.0x n/a Merck & Co., Inc. completed the acquisition of Harpoon Therapeutics, Inc. at $88M. Disclosed values of this size are consistent with cash-adjusted pricing, where the target's balance sheet is credited close to dollar for dollar. Apr-2024 Kintara Therapeutics, Inc. → TuHURA Biosciences, Inc. $5M n/a n/a Kintara Therapeutics, Inc. completed a transaction with TuHURA Biosciences, Inc. recorded at $5M. The size and shape are consistent with the reverse-merger route into a cash-carrying listed company, a recognised path to the public market for private developers here. Jan-2024 Bruckman, Rosser, Sherril & Co. Inc. → Junshi Biosciences, Co., Ltd. n/a n/a 8.6x Bruckman, Rosser, Sherril & Co. Inc. announced a transaction for Junshi Biosciences, Co., Ltd. recorded at 8.6x EBITDA, with no enterprise value disclosed. Financial buyers in this sector tend to concentrate on operating businesses at the edge of it rather than on… Nov-2023 AbbVie Inc. → ImmunoGen, Inc. n/a 9.9x n/a AbbVie Inc. announced the acquisition of ImmunoGen, Inc. at 9.9x revenue, with no enterprise value disclosed here. The mark sits above the middle of the peer set on a revenue basis, alongside a target with linker-payload chemistry of its own.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists the second half of the precedent transactions with disclosed terms, ordered newest first.

    This second table continues the same precedent list, still ordered newest first and still linked back to the underlying filings. Together with the prior page, it completes the disclosed-terms record behind the deal commentary shown earlier. So what: a client tracing any single transaction's terms can do so directly from this page.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 16 transactions with disclosed terms in this tier (53 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 67 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2023 Jazz Pharmaceuticals, Inc. → Zymeworks Zanidatamab Inc. $471M 1.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2022 Sesen Bio, Inc. → Carisma Therapeutics Inc. $628M 26.7x n/a Value shown as recorded in the filing; deal value unit unresolved. Jul-2020 EnCana → Compass Therapeutics LLC n/a n/a 6.6x Value shown as recorded in the filing; deal value unit unresolved. May-2020 Sanofi → Regeneron $64.1B 9.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2020 Gilead Sciences, Inc. → Forty Seven, Inc. n/a 1.8x n/a May-2017 Norgine → Merus Labs n/a 3.3x n/a Value shown as recorded in the filing; deal value unit unresolved. n/a Sanofi S.A. → Inhibrx Biosciences, Inc. $1.9B n/a n/a Value shown as recorded in the filing; deal value unit unresolved.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page documents the report's sources, assumptions and data-quality treatment.

    We use this page to show how the report was built: what basis was used, what was excluded, and where every underlying disclosure lives. Every figure in the report links back to the filing or estimate it was drawn from wherever a link exists. So what: this is the page to point to when a client asks how a specific number in the deck was derived.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (32 of 63 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (32 of 63 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Antibody and Protein Therapeutics and it clears the coverage gate with 32 of 63 companies (51%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (6 of 63 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 304 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1526 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1525) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    One Sector Label, Three Price Tiers, and the Spread Sits Inside the Clinical-Stage Group.

    This is the closing page restating that one sector label covers three price tiers, with the spread sitting inside the clinical-stage group.

    We close on the same line we opened with: one sector label, three price tiers, and the spread sits inside the clinical-stage group. The companion tables carry the full universe and source index for any figure a client wants to trace further — so what: the tier you sit in inside that clinical-stage group, not the sector label itself, is what should shape your next conversation.

    Everything on this page

    One Sector Label, Three Price Tiers, and the Spread Sits Inside the Clinical-Stage Group. NeuraCap AI — Antibody and Protein Therapeutics Coverage September 2026 · Prepared by NeuraCap AI · Confidential Antibody and Protein Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Antibody and Protein Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Antibody and Protein Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 63 listed companies whose core business is Antibody and Protein Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Acumen Pharmaceuticals, Inc. (ABOS), Absci Corporation (ABSI), Adagene Inc. (ADAG), ADC Therapeutics S.A. (ADCT), ADMA Biologics, Inc. (ADMA), Agenus Inc. (AGEN), Alector, Inc. (ALEC), ALX Oncology Holdings Inc. (ALXO), Annexon, Inc. (ANNX), argenx SE (ARGX), Avalo Therapeutics, Inc. (AVTX), Bicara Therapeutics Inc. Common Stock (BCAX), BioMarin Pharmaceutical Inc. (BMRN), Cullinan Therapeutics, Inc. (CGEM), Compugen Ltd. (CGEN), Celldex Therapeutics, Inc. (CLDX), Compass Therapeutics, Inc. (CMPX), Connect Biopharma Holdings Limited (CNTB), Context Therapeutics Inc. (CNTX), Coya Therapeutics, Inc. (COYA), Corvus Pharmaceuticals, Inc. (CRVS), CytomX Therapeutics, Inc. (CTMX), DiaMedica Therapeutics Inc. (DMAC), Dianthus Therapeutics, Inc. (DNTH), Genmab A/S (GMAB), Grifols, S.A. (GRFS), ImmunityBio, Inc. (IBRX), ImmuCell Corporation (ICCC), InflaRx N.V. (IFRX), ImageneBio Inc (IMA), Immunovant, Inc. (IMVT), Inhibrx Biosciences, Inc. (INBX), Invivyd, Inc. (IVVD), Janux Therapeutics, Inc. (JANX), Jade Biosciences, Inc. (JBIO), Kamada Ltd. (KMDA), Kiniksa Pharmaceuticals, Ltd. (KNSA), Kodiak Sciences Inc. (KOD), Keros Therapeutics, Inc. (KROS), MoonLake Immunotherapeutics (MLTX), OmniAb, Inc. (OABI), Omeros Corporation (OMER), Oruka Therapeutics, Inc. (ORKA), Prothena Corporation plc (PRTA), Pyxis Oncology, Inc. (PYXS), Arcus Biosciences, Inc. (RCUS), Roivant Sciences Ltd. (ROIV), Rezolute, Inc. (RZLT), Scholar Rock Holding Corporation

Scope and company universe

This report covers Antibody and Protein Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Antibody and Protein Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 63 listed companies whose core business is Antibody and Protein Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Acumen Pharmaceuticals, Inc. (ABOS), Absci Corporation (ABSI), Adagene Inc. (ADAG), ADC Therapeutics S.A. (ADCT), ADMA Biologics, Inc. (ADMA), Agenus Inc. (AGEN), Alector, Inc. (ALEC), ALX Oncology Holdings Inc. (ALXO), Annexon, Inc. (ANNX), argenx SE (ARGX), Avalo Therapeutics, Inc. (AVTX), Bicara Therapeutics Inc. Common Stock (BCAX), BioMarin Pharmaceutical Inc. (BMRN), Cullinan Therapeutics, Inc. (CGEM), Compugen Ltd. (CGEN), Celldex Therapeutics, Inc. (CLDX), Compass Therapeutics, Inc. (CMPX), Connect Biopharma Holdings Limited (CNTB), Context Therapeutics Inc. (CNTX), Coya Therapeutics, Inc. (COYA), Corvus Pharmaceuticals, Inc. (CRVS), CytomX Therapeutics, Inc. (CTMX), DiaMedica Therapeutics Inc. (DMAC), Dianthus Therapeutics, Inc. (DNTH), Genmab A/S (GMAB), Grifols, S.A. (GRFS), ImmunityBio, Inc. (IBRX), ImmuCell Corporation (ICCC), InflaRx N.V. (IFRX), ImageneBio Inc (IMA), Immunovant, Inc. (IMVT), Inhibrx Biosciences, Inc. (INBX), Invivyd, Inc. (IVVD), Janux Therapeutics, Inc. (JANX), Jade Biosciences, Inc. (JBIO), Kamada Ltd. (KMDA), Kiniksa Pharmaceuticals, Ltd. (KNSA), Kodiak Sciences Inc. (KOD), Keros Therapeutics, Inc. (KROS), MoonLake Immunotherapeutics (MLTX), OmniAb, Inc. (OABI), Omeros Corporation (OMER), Oruka Therapeutics, Inc. (ORKA), Prothena Corporation plc (PRTA), Pyxis Oncology, Inc. (PYXS), Arcus Biosciences, Inc. (RCUS), Roivant Sciences Ltd. (ROIV), Rezolute, Inc. (RZLT), Scholar Rock Holding Corporation (SRRK), Sutro Biopharma, Inc. (STRO), Shattuck Labs, Inc. (STTK), Savara Inc. (SVRA), Tectonic Therapeutic, Inc. (TECX), TG Therapeutics, Inc. (TGTX), Tiziana Life Sciences Ltd (TLSA), Upstream Bio, Inc. (UPB), Vir Biotechnology, Inc. (VIR), Viridian Therapeutics, Inc. (VRDN), Whitehawk Therapeutics Inc (WHWK), XBiotech Inc. (XBIT), Xencor, Inc. (XNCR), Zenas BioPharma, Inc. (ZBIO), Zura Bio Limited (ZURA). The market map groups them by business vertical — Clinical-stage biologics developers: 60 companies (ARGX, GMAB, ROIV, BMRN, IBRX, TGTX, IMVT, SRRK, KOD, ORKA, DNTH, RCUS, ADMA, XNCR, CLDX, VRDN, INBX, ABSI, OMER, VIR, ZBIO, SVRA, CRVS, BCAX, OABI, ANNX, MLTX, CGEM, STTK, JBIO, DMAC, AGEN, AVTX, RZLT, CTMX, TECX, ZURA, PYXS, PRTA, ICCC, IVVD, CGEN, IFRX, STRO, JANX, ABOS, ADAG, COYA, ALXO, WHWK, TLSA, ADCT, ALEC, CNTB, CMPX, CNTX, IMA, KROS, UPB, XBIT); Adjacent models: 3 companies (GRFS, KNSA, KMDA). 32 of the 63 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

304 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 266 excluded from aggregate; 37 quarantined). Each exclusion, with its reason: NBP — The ticker NBP carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · ABOS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABOS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABSI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABSI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABSI — Implied EBITDA margin -2687.1% outside the plausible band [-100%, 80%] (effect: quarantined) · ABSI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABSI — Implied EBITDA margin -567.2% outside the plausible band [-100%, 80%] (effect: quarantined) · ABSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADAG — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ADAG — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ADAG — Implied EBITDA margin -765.1% outside the plausible band [-100%, 80%] (effect: quarantined) · ADAG — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ADAG — Implied EBITDA margin -798.3% outside the plausible band [-100%, 80%] (effect: quarantined) · ADAG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADAG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADAG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADAG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (32 of 63 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (32 of 63 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Antibody and Protein Therapeutics and it clears the coverage gate with 32 of 63 companies (51%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (6 of 63 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 6 of 63 companies; EV / rEVenue: 50 of 63 companies; P/E: 6 of 63 companies. 3 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 51 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥12.1x, Core 2.4x–12.1x, Discount <2.4x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 5.8x = median(ev_revenue CY2027E) (32 rated companies) · 17.6x = median(ev_revenue CY2027E) within Premium tier (n=8) · 5.8x = median(ev_revenue CY2027E) within Core tier (n=16) · 1.2x = median(ev_revenue CY2027E) within Discount tier (n=8) · 6.7x = median(ev_revenue CY2027E) | growth ≥ 18% (n=13) · 3.2x = median(ev_revenue CY2027E) | growth < 18% (n=12) · 4.9x = median(ev_revenue CY2027E) | EBITDA margin ≥ 32% (n=3) · 2.0x = median(ev_revenue CY2027E) | EBITDA margin < 32% (n=3) · 47% = median Rule of 40 score (revenue growth + EBITDA margin) (n=6)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Antibody and Protein Therapeutics recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 53 transactions were recorded for this industry; 16 are shown. 37 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 31 × deal value unit unresolved; 32 × no evidence record; 2 × duplicate precedent id; 2 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 1530 source documents stand behind this report; by publisher domain: sec.gov (1525), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Antibody and Protein Therapeutics?

Company valuation reports run the same method against a single business — public or private.